A control optimization method for array-type photoacoustic transdermal patches

By acquiring the geometric deformation data of the flexible patch and inverting the equivalent sound velocity from the echo signal in real time, the wavefront distortion and focusing inaccuracy caused by the non-uniformity of human tissue in traditional transdermal drug delivery systems have been solved, achieving efficient and safe transdermal drug delivery.

CN123059262APending Publication Date: 2026-11-10UNIV OF ELECTRONICS SCI & TECH OF CHINA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611084338.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-07-21
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Traditional transdermal drug delivery systems cannot adapt to the non-uniformity of human tissues and individual differences, resulting in wavefront distortion and focusing inaccuracy, which poses risks of energy waste or local overheating. Existing solutions lack accurate modeling of the intrinsic response characteristics of acoustic metamaterial arrays.

Method used

By integrating a strain sensing network of flexible patches to collect geometric deformation data in real time, the actual physical coordinates of the photoacoustic transducer array are calculated, the equivalent sound velocity of the tissue medium is inverted using the echo signal, the propagation path delay is calculated and a composite driving signal is generated to excite the acoustic metamaterial array to generate resonant acoustic flow, and the cumulative drug dose is monitored in real time.

Benefits of technology

It achieves precise focusing on human tissues, avoiding energy waste and local overheating, and ensuring the safety and effectiveness of drug delivery.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123059262A_ABST
    Figure CN123059262A_ABST
Patent Text Reader

Abstract

This invention discloses a control optimization method for an array-type photoacoustic transdermal patch, relating to the field of biomedical engineering technology. The method includes: real-time acquisition of geometric deformation data of the patch via a strain sensing network integrated into the flexible patch; calculation of the actual physical coordinates of each element in the photoacoustic transducer array in three-dimensional space based on the geometric deformation data; emission of probe acoustic pulses to the target tissue and reception of echo signals; inversion of the equivalent sound velocity of the tissue medium based on the phase characteristics of the echo signals; calculation of the propagation path delay from each element to a preset focus based on the actual physical coordinates and equivalent sound velocity; calculation of the theoretical sound intensity distribution required for focusing based on the propagation path delay; calculation of the initial excitation power density required to drive the acoustic metamaterial array based on the theoretical sound intensity distribution and the material property parameters of the acoustic metamaterial; and generation of a composite driving signal containing timing control and amplitude modulation based on the propagation path delay and the initial excitation power density.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of biomedical engineering technology, and in particular to a method for controlling and optimizing an array-type photoacoustic transdermal patch. Background Technology

[0002] Transdermal drug delivery systems have become an important research area in drug delivery due to their advantages such as being non-invasive, having high patient compliance, and avoiding the first-pass effect. In recent years, with the deep integration of micro-nano manufacturing technology, flexible electronics, and acousto-optic modulation technology, smart transdermal patches based on physical field enhancement are gradually replacing traditional passive diffusion patches and becoming the mainstream of the next generation of transdermal therapeutic devices.

[0003] Human tissues exhibit high acoustic non-uniformity, with differences in sound velocity between different individuals and anatomical layers. Traditional systems use fixed sound velocity parameters for time delay calculations, which cannot adapt to changes in the medium characteristics of the actual propagation path, leading to wavefront distortion and focusing inaccuracy. Existing solutions lack accurate modeling of the intrinsic response characteristics of acoustic metamaterial arrays, and there is a nonlinear mismatch between driving power and output sound intensity, which can easily cause energy waste or local overheating risks. Summary of the Invention

[0004] In view of the aforementioned existing problems, the present invention is proposed.

[0005] Therefore, this invention provides a control optimization method for array-type photoacoustic transdermal patches to solve the sound velocity differences between different individuals and anatomical layers. Traditional systems use fixed sound velocity parameters for time delay calculation, which cannot adapt to the changes in the medium characteristics of the actual propagation path, thus causing wavefront distortion and focusing inaccuracy. Existing solutions lack accurate modeling of the intrinsic response characteristics of acoustic metamaterial arrays, and there is a nonlinear mismatch between driving power and output sound intensity, which can easily cause energy waste or local overheating risks.

[0006] To solve the above-mentioned technical problems, the present invention provides the following technical solution: In a first aspect, the present invention provides a control optimization method for an array-type photoacoustic transdermal patch, which includes: acquiring geometric deformation data of the patch in real time through a strain sensing network integrated into the flexible patch, and calculating the actual physical coordinates of each element in the photoacoustic transducer array in three-dimensional space based on the geometric deformation data. The probe acoustic pulse is emitted to the target tissue and the echo signal is received. The equivalent sound velocity of the tissue medium is obtained by inversion based on the phase characteristics of the echo signal. The propagation path delay from each array element to the preset focus is calculated based on the actual physical coordinates and the equivalent sound velocity, and the theoretical sound intensity distribution required to achieve focusing is calculated based on the propagation path delay. Based on the theoretical sound intensity distribution and the material property parameters of the acoustic metamaterial, the initial excitation power density required to drive the acoustic metamaterial array is calculated. A composite driving signal containing timing control and amplitude modulation is generated based on the propagation path delay and the initial excitation power density. The composite driving signal is used to excite the acoustic metamaterial array to generate resonant acoustic flow to perform transdermal drug delivery, and photoacoustic feedback signals inside the tissue are collected simultaneously. The cumulative drug dose is monitored in real time based on the photoacoustic feedback signal, and the drive signal output is terminated when the preset threshold is reached.

[0007] As a preferred embodiment of the control and optimization method for the array-type photoacoustic transdermal patch of the present invention, the steps are as follows: The geometric deformation data of the patch is collected in real time through a strain sensing network integrated into the flexible patch, and the actual physical coordinates of each element in the photoacoustic transducer array in three-dimensional space are calculated based on the geometric deformation data. By utilizing a distributed fiber optic grating sensor array pre-integrated within the flexible patch substrate, the axial tensile strain and bending strain generated after the patch is applied to the surface of human skin are monitored in real time, and the wavelength drift data of each sensor node due to deformation is obtained. The wavelength drift data is input into the polynomial surface fitting algorithm model, and the three-dimensional surface geometric equation of the flexible patch in the current application state is reconstructed through spatial interpolation. Based on the aforementioned three-dimensional surface geometric equations, a coordinate transformation matrix is ​​used to perform nonlinear mapping operations on the preset relative position vectors of the array elements, thereby accurately calculating the actual physical coordinates of each array element in the photoacoustic transducer array in three-dimensional space. ; Among them, calculating the actual physical coordinates The expression is: ; in, Indicates the first The actual three-dimensional spatial coordinate vector of each array element in the applied state. Indicates the overall bending angle of the patch. and torsion angle The constructed rigid body rotation matrix, This represents the initial position vector of the array element when the flexible patch is in an undeformed planar state. This represents the surface strain distribution function acquired by a distributed fiber Bragg grating sensor array. This represents the scalar potential gradient operator that describes the deformation gradient of the flexible patch surface. This represents the integral surface area region of the flexible patch.

[0008] As a preferred embodiment of the control and optimization method for the array-type photoacoustic transdermal patch of the present invention, the steps of transmitting a probe acoustic pulse to the target tissue and receiving the echo signal, and obtaining the equivalent sound velocity of the tissue medium based on the phase characteristics of the echo signal, are as follows: The central array element in the photoacoustic transducer array is controlled to emit broadband ultrasonic detection pulses into the deep target tissue, while the receiving array elements at the edge of the array are used to capture the echo signal scattered by the tissue medium. The echo signal is subjected to Hilbert transform processing, envelope detection and instantaneous phase extraction to obtain high-precision instantaneous phase difference data; A sound velocity inversion model based on the time-of-flight method and phase correction is constructed. The instantaneous phase difference data is used to correct the propagation time of sound waves in tissue, thereby obtaining the equivalent sound velocity in the tissue medium. ; Among them, the equivalent sound velocity of the tissue medium is calculated. The expression is: ; in, This represents the equivalent average sound velocity of the tissue medium obtained through inversion. This indicates the physical distance between the center of the transmitting element and the center of the receiving element. This represents the time flight delay of the echo signal envelope peak relative to the start of the transmitted pulse. Indicates the center frequency of the detected acoustic pulse. This represents the complex analytic signal after the echo signal undergoes the Hilbert transform. The operator represents the operation of taking the imaginary part of a complex number. Operators that take the real part of a complex number.

[0009] As a preferred embodiment of the control and optimization method for the array-type photoacoustic transdermal patch of the present invention, the specific steps of calculating the propagation path delay from each array element to the preset focus based on the actual physical coordinates and the equivalent sound velocity, and calculating the theoretical sound intensity distribution required to achieve focusing based on the propagation path delay, are as follows: Using the Euclidean distance formula, the straight-line distance between the actual physical coordinates of each element in the photoacoustic transducer array in three-dimensional space and the coordinates of the preset treatment focus is calculated to obtain the geometric propagation distance of each element. Divide the geometric propagation distance by the equivalent sound speed of the tissue medium and normalize the result to obtain the initial propagation delay of each array element. An acoustic attenuation coefficient is introduced to nonlinearly compensate for the initial propagation delay, thereby offsetting the energy loss and phase distortion of sound waves propagating in non-uniform structures and determining the propagation path delay of each array element. ; Among them, the propagation path delay is calculated. The expression is: ; in, Indicates the first The propagation path delay of each array element to the preset focus. Indicates the first The actual physical coordinates of each array element in three-dimensional space The spatial coordinate vector representing the preset treatment focus. Operators representing Euclidean norms Represents the equivalent speed of sound in the tissue medium. The attenuation factor represents the non-uniformity of the tissue medium. This represents the characteristic attenuation length constant of sound waves in tissue.

[0010] As a preferred embodiment of the control and optimization method for the array-type photoacoustic transdermal patch of the present invention, the step of calculating the initial excitation power density required to drive the acoustic metamaterial array based on the theoretical sound intensity distribution and the material property parameters of the acoustic metamaterial includes the following steps: Based on the piezoelectric constitutive equation, the electromechanical coupling coefficient and dielectric loss of the acoustic metamaterial array are mathematically modeled, and the energy conversion efficiency factor is calculated. Based on the theoretical sound intensity distribution, the energy density requirement value required to achieve an effective therapeutic effect at the target focal point is defined. By using a nonlinear acoustic flow effect model, the energy conversion efficiency factor and the energy density requirement are coupled and calculated to determine the initial excitation power density required to drive the acoustic metamaterial array. ; Among them, the initial excitation power density is calculated. The expression is: ; in, This represents the initial excitation power density required to drive the acoustic metamaterial array. This represents the target intensity value of the theoretical sound intensity distribution required to achieve focusing. This indicates the electromechanical coupling energy conversion efficiency of acoustic metamaterials. The acoustic nonlinear parameters representing the tissue medium, Indicates the density of the target tissue. It represents the equivalent speed of sound in the tissue medium.

[0011] As a preferred embodiment of the control optimization method for the array-type photoacoustic transdermal patch of the present invention, the specific steps of generating a composite driving signal containing timing control and amplitude modulation based on the propagation path delay and the initial excitation power density are as follows: High-frequency carrier pulse sequences are generated using field-programmable gate arrays (FPGAs). Based on the propagation path delay, digital phase shift control is performed on each channel of the high-frequency carrier pulse sequence to generate precise timing control components. Based on the initial excitation power density, the pulse duty cycle of the timing control component is pulse-width modulated to generate the corresponding amplitude modulation component; The timing control component and the amplitude modulation component are logically superimposed and synthesized to generate a composite drive signal for driving the transducer.

[0012] As a preferred embodiment of the control and optimization method for the array-type photoacoustic transdermal patch of the present invention, the steps of using the composite driving signal to excite the acoustic metamaterial array to generate resonant acoustic flow to perform transdermal drug delivery, and simultaneously acquiring photoacoustic feedback signals from within the tissue, are as follows: The composite driving signal is applied to the piezoelectric excitation end of the acoustic metamaterial array to excite the acoustic flow effect at the micro-nano scale, and instantaneously open the skin stratum corneum channel to perform transdermal drug delivery. By utilizing a photodiode array integrated on the back of the patch, the photoacoustic response light waves generated by the stimulation of drug molecules inside the tissue can be received in real time. Lock-in amplification technology is applied to perform high signal-to-noise ratio noise reduction on the photoacoustic response light wave, and the photoacoustic feedback signal is accurately extracted from it.

[0013] As a preferred embodiment of the control and optimization method for the array-type photoacoustic transdermal patch of the present invention, the step of monitoring the cumulative drug dose in real time based on the photoacoustic feedback signal and terminating the output of the driving signal when a preset threshold is reached includes the following steps: Based on the acoustic equivalent form of Lambert-Beer's law, the amplitude of the photoacoustic feedback signal is analyzed to calculate the real-time transient drug concentration. Using the trapezoidal integral rule, the transient drug concentration is continuously accumulated over the dosing time axis to obtain the cumulative drug dose. ; Among them, the cumulative drug dose is calculated. The expression is: ; in, This indicates the real-time cumulative drug dose. Indicates the moment when transdermal drug delivery begins. Indicates the current system time. This represents the photoacoustic conversion efficiency constant of drug molecules. express The amplitude of the photoacoustic feedback signal collected at all times, This represents the system background noise floor amplitude. This represents the natural logarithm operator.

[0014] In a second aspect, the present invention provides a computer device including a memory and a processor, wherein the memory stores a computer program, wherein when the computer program is executed by the processor, it implements any step of the control optimization method for array-type photoacoustic transdermal patches as described in the first aspect of the present invention.

[0015] Thirdly, the present invention provides a computer-readable storage medium having a computer program stored thereon, wherein: when the computer program is executed by a processor, it implements any step of the control optimization method for array-type photoacoustic transdermal patches as described in the first aspect of the present invention.

[0016] The beneficial effects of this invention are as follows: By inverting the equivalent sound velocity of tissue based on the phase characteristics of the echo signal, it overcomes the limitation of traditional equipment that uses a fixed sound velocity assumption, which cannot adapt to the non-uniformity of human tissue and individual differences. It solves the problem of phase distortion caused by medium mismatch, provides real physical parameter support for deep focusing, and combines real coordinates and sound velocity to calculate nonlinear propagation delay and plan theoretical sound intensity distribution. This effectively offsets the energy loss and defocusing effect of sound waves in non-uniform media, and realizes high energy density convergence and sidelobe suppression at the focal point. Attached Figure Description

[0017] To more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings used in the following description of the embodiments will be briefly introduced. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0018] Figure 1 A flowchart of a control optimization method for array-type photoacoustic transdermal patches. Detailed Implementation

[0019] To make the above-mentioned objects, features and advantages of the present invention more apparent and understandable, the specific embodiments of the present invention will be described in detail below with reference to the accompanying drawings.

[0020] Many specific details are set forth in the following description in order to provide a full understanding of the invention. However, the invention may also be practiced in other ways different from those described herein, and those skilled in the art can make similar extensions without departing from the spirit of the invention. Therefore, the invention is not limited to the specific embodiments disclosed below.

[0021] Secondly, the term "one embodiment" or "embodiment" as used herein refers to a specific feature, structure, or characteristic that may be included in at least one implementation of the present invention. The phrase "in one embodiment" appearing in different places in this specification does not necessarily refer to the same embodiment, nor is it a single or selective embodiment that is mutually exclusive with other embodiments.

[0022] Reference Figure 1 As one embodiment of the present invention, this embodiment provides a control optimization method for an array-type photoacoustic transdermal patch, comprising the following steps: S1. The geometric deformation data of the patch is collected in real time by the strain sensing network integrated into the flexible patch, and the actual physical coordinates of each element in the photoacoustic transducer array in three-dimensional space are calculated based on the geometric deformation data.

[0023] Furthermore, by utilizing a distributed fiber optic grating sensor array pre-integrated within the flexible patch substrate, the axial tensile strain and bending strain generated after the patch is applied to the surface of human skin are dynamically monitored in real time, and the wavelength drift data of each sensor node due to deformation is obtained. The wavelength drift data is input into the polynomial surface fitting algorithm model, and the three-dimensional surface geometric equation of the flexible patch under the current application state is reconstructed through spatial interpolation. Based on the three-dimensional surface geometric equations, a coordinate transformation matrix is ​​used to perform nonlinear mapping operations on the preset relative position vectors of the array elements, thereby accurately calculating the actual physical coordinates of each array element in the photoacoustic transducer array in three-dimensional space. ; Among them, calculating the actual physical coordinates The expression is: ; in, Indicates the first The actual three-dimensional spatial coordinate vector of each array element in the applied state. Indicates the overall bending angle of the patch. and torsion angle The constructed rigid body rotation matrix, This represents the initial position vector of the array element when the flexible patch is in an undeformed planar state. This represents the surface strain distribution function acquired by a distributed fiber Bragg grating sensor array. This represents the scalar potential gradient operator that describes the deformation gradient of the flexible patch surface. This represents the integral surface area region of the flexible patch.

[0024] It should be noted that in the prior art, when the flexible patch is attached to the irregular and non-rigid skin surface of the human body, its geometric deformation will cause the preset transducer array spatial position to shift. If it is not corrected, this shift will directly lead to the failure of subsequent sound beam focusing, which will seriously affect the treatment accuracy.

[0025] By introducing a distributed fiber Bragg grating sensor array as a "nervous system," the microscopic strain of the patch is sensed in real time. Through polynomial surface fitting and nonlinear mapping of coordinate transformation matrices, physical deformation data is transformed into precise spatial coordinate correction values, solving the spatial mapping problem between flexible devices and rigid electronic systems. Furthermore, through mathematical modeling, continuous physical deformation is discretized into calculable digital signals, fundamentally ensuring that the input reference of the subsequent focusing algorithm is accurate. This is a prerequisite for achieving high-precision transdermal drug delivery and avoids systematic errors caused by carrier deformation.

[0026] S2. A probe acoustic pulse is emitted to the target tissue and the echo signal is received. The equivalent sound velocity of the tissue medium is obtained by inversion based on the phase characteristics of the echo signal.

[0027] Furthermore, the central element in the photoacoustic transducer array is controlled to emit broadband ultrasonic detection pulses into the deep target tissue, while the receiving elements at the edge of the array capture the echo signal scattered by the tissue medium. The echo signal is processed by Hilbert transform, envelope detection and instantaneous phase extraction are performed to obtain high-precision instantaneous phase difference data; A sound velocity inversion model based on the time-of-flight method and phase correction is constructed. The propagation time of sound waves in tissue is corrected and calculated using instantaneous phase difference data, thereby obtaining the equivalent sound velocity in the tissue medium. ; Among them, the equivalent sound velocity of the tissue medium is calculated. The expression is: ; in, This represents the equivalent average sound velocity of the tissue medium obtained through inversion. This indicates the physical distance between the center of the transmitting element and the center of the receiving element. This represents the time flight delay of the echo signal envelope peak relative to the start of the transmitted pulse. Indicates the center frequency of the detected acoustic pulse. This represents the complex analytic signal after the echo signal undergoes the Hilbert transform. The operator represents the operation of taking the imaginary part of a complex number. Operators that take the real part of a complex number.

[0028] It should be noted that a fixed average sound velocity value is usually used for calculation. However, human tissue has a high degree of non-uniformity and individual differences. If a fixed value is used, the sound wave will undergo phase distortion during propagation, resulting in blurred or even deviated focus. This solution creatively utilizes the array's own transmission and reception functions to construct a "self-detection-self-correction" mechanism.

[0029] By introducing Hilbert transform to extract instantaneous phase, minute waveform changes can be captured. Then, the equivalent speed of sound under a specific path can be inverted through time-flight and phase correction models. By using measured data to adapt to complex physiological environments, the focusing error caused by sound speed mismatch in traditional methods can be overcome. It also realizes dynamic perception of the acoustic characteristics of specific individuals and specific paths, providing real and reliable physical parameters for subsequent accurate time delay calculation.

[0030] S3. Calculate the propagation path delay from each array element to the preset focus based on the actual physical coordinates and equivalent sound velocity, and calculate the theoretical sound intensity distribution required to achieve focusing based on the propagation path delay.

[0031] Furthermore, using the Euclidean distance formula, the straight-line distance between the actual physical coordinates of each element in the photoacoustic transducer array in three-dimensional space and the coordinates of the preset treatment focus is calculated to obtain the geometric propagation distance of each element. Divide the geometric propagation distance by the equivalent sound speed of the organization medium and normalize it to obtain the initial propagation delay of each array element. An acoustic attenuation coefficient is introduced to nonlinearly compensate for the initial propagation delay, thereby offsetting the energy loss and phase distortion of sound waves propagating in non-uniform structures and determining the propagation path delay of each array element. ; Among them, the propagation path delay is calculated. The expression is: ; in, Indicates the first The propagation path delay of each array element to the preset focus. Indicates the first The actual physical coordinates of each array element in three-dimensional space The spatial coordinate vector representing the preset treatment focus. Operators representing Euclidean norms Represents the equivalent speed of sound in the tissue medium. The attenuation factor represents the non-uniformity of the tissue medium. This represents the characteristic attenuation length constant of sound waves in tissue.

[0032] It should be noted that nonlinear compensation is achieved by introducing a sound attenuation coefficient. This is because sound wave energy decreases exponentially with propagation distance, and different tissues have different absorption coefficients for sound waves. Without compensation, the energy of distant array elements will be weaker than that of nearby array elements when they reach the focal point, resulting in uneven energy distribution at the focal point.

[0033] By embedding an attenuation correction factor in the time delay calculation, the loss in the amplitude domain is actually pre-compensated in the time domain. This reflects a profound understanding of the physical laws of sound wave propagation. That is, by precisely controlling the minute differences in the transmission time, the energy loss in the propagation process is offset, ensuring that the sound waves of all array elements can be superimposed at the focal point with "same amplitude and phase".

[0034] S4. Based on the theoretical sound intensity distribution and the material properties of the acoustic metamaterial, calculate the initial excitation power density required to drive the acoustic metamaterial array.

[0035] Furthermore, based on the piezoelectric constitutive equation, the electromechanical coupling coefficient and dielectric loss of the acoustic metamaterial array are mathematically modeled, and the energy conversion efficiency factor is calculated. Based on the theoretical sound intensity distribution, the energy density requirement value required to achieve an effective therapeutic effect at the target focal point is defined. By using a nonlinear acoustic flow effect model, the energy conversion efficiency factor and the energy density requirement are coupled and calculated to determine the initial excitation power density required to drive the acoustic metamaterial array. ; Among them, the initial excitation power density is calculated. The expression is: ; in, This represents the initial excitation power density required to drive the acoustic metamaterial array. This represents the target intensity value of the theoretical sound intensity distribution required to achieve focusing. This indicates the electromechanical coupling energy conversion efficiency of acoustic metamaterials. The acoustic nonlinear parameters representing the tissue medium, Indicates the density of the target tissue. It represents the equivalent speed of sound in the tissue medium.

[0036] It should be noted that the material properties of acoustic metamaterials and the biophysical properties of tissues are incorporated into a unified mathematical model because different transducer materials have different efficiencies in converting electrical energy into acoustic energy, and tissues exhibit nonlinear absorption characteristics under high acoustic intensity. By establishing the coupling relationship between the piezoelectric constitutive equation and the nonlinear acoustic flow effect model, it is possible to accurately deduce how much initial power needs to be applied at the driving end in order to achieve the target acoustic intensity Itarget at the focal point.

[0037] This avoids tissue thermal damage caused by blindly increasing power, or low drug delivery efficiency caused by insufficient power. It embodies a shift from "extensive" to "refined" energy management, ensuring the safety and effectiveness of treatment.

[0038] S5. Based on the theoretical sound intensity distribution and the material properties of the acoustic metamaterial, calculate the initial excitation power density required to drive the acoustic metamaterial array.

[0039] Furthermore, a high-frequency carrier pulse sequence can be generated using a field-programmable gate array (FPGA). Based on the propagation path delay, digital phase shift control is performed on each channel of the high-frequency carrier pulse sequence to generate precise timing control components. Based on the initial excitation power density, the pulse duty cycle of the timing control component is pulse-width modulated to generate the corresponding amplitude modulation component; The timing control component and the amplitude modulation component are logically superimposed and synthesized to generate a composite drive signal for driving the transducer.

[0040] It should be noted that a field-programmable gate array (FPGA) hardware platform is used, achieving nanosecond-level delay control through digital phase shifting and milliwatt-level power control through pulse width modulation. This is based on a deep understanding of the characteristics of real-time embedded systems: only hardware logic can guarantee the consistency of multi-channel signals on a microsecond-level time scale. By logically superimposing the timing and amplitude components, a composite signal containing both spatial phase and energy amplitude information is generated.

[0041] It ensures that the theoretically perfect sound field can be reproduced in the physical world with high fidelity. It is a bridge connecting digital algorithms and the simulated physical world, and a key hardware implementation to ensure the stable operation of the entire closed-loop control system.

[0042] S6. A composite driving signal is used to excite an acoustic metamaterial array to generate resonant acoustic flow to perform transdermal drug delivery, while simultaneously acquiring photoacoustic feedback signals from inside the tissue.

[0043] Furthermore, a composite driving signal is applied to the piezoelectric excitation end of the acoustic metamaterial array to excite the acoustic flow effect at the micro-nano scale, which instantaneously opens the skin stratum corneum channel to perform transdermal drug delivery. By utilizing a photodiode array integrated on the back of the patch, the photoacoustic response light waves generated by the stimulation of drug molecules inside the tissue can be received in real time. Lock-in amplification technology is used to perform high signal-to-noise ratio noise reduction on the photoacoustic response light wave, and the photoacoustic feedback signal is accurately extracted from it.

[0044] It should be noted that the use of acoustic metamaterials to excite micro- and nano-acoustic flow physically opens the skin barrier, allowing the system to "see" the destination and accumulation of drugs while administering them. This is not merely a simple functional superposition, but a clever utilization of the interaction of physical fields. It provides necessary data support for achieving precision medicine, avoids the risks of blind drug administration, and is a necessary prerequisite for realizing intelligent and automated transdermal drug delivery systems.

[0045] S7. Monitor the cumulative drug dosage in real time based on the photoacoustic feedback signal, and terminate the drive signal output when the preset threshold is reached.

[0046] Furthermore, based on the acoustic equivalent form of the Lambert-Beer law, the amplitude of the photoacoustic feedback signal is analyzed to calculate the real-time transient drug concentration. The trapezoidal integral rule is used to continuously accumulate transient drug concentrations over the dosing time axis to obtain the cumulative drug dose. ; Among them, the cumulative drug dose is calculated. The expression is: ; in, This indicates the real-time cumulative drug dose. Indicates the moment when transdermal drug delivery begins. Indicates the current system time. This represents the photoacoustic conversion efficiency constant of drug molecules. express The amplitude of the photoacoustic feedback signal collected at all times, This represents the system background noise floor amplitude. This represents the natural logarithm operator.

[0047] It should be noted that a quantitative relationship is established between the amplitude of the photoacoustic signal and the drug concentration, and the cumulative dose is obtained through time integration, and calculated through real-time integration. By comparing the dosage with a preset threshold, the system can autonomously determine when to stop administering the medication. This not only avoids the toxic side effects caused by overdose but also prevents ineffective treatment due to insufficient dosage.

[0048] This embodiment also provides a computer device applicable to the control optimization method of an array-type photoacoustic transdermal patch, comprising: a memory and a processor; the memory is used to store computer-executable instructions, and the processor is used to execute the computer-executable instructions to implement the control optimization method of the array-type photoacoustic transdermal patch as proposed in the above embodiment.

[0049] The computer device can be a terminal, comprising a processor, memory, communication interface, display screen, and input devices connected via a system bus. The processor provides computing and control capabilities. The memory includes non-volatile storage media and internal memory. The non-volatile storage media stores the operating system and computer programs. The internal memory provides an environment for the operation of the operating system and computer programs stored in the non-volatile storage media. The communication interface is used for wired or wireless communication with external terminals; wireless communication can be achieved through Wi-Fi, carrier networks, NFC (Near Field Communication), or other technologies. The display screen can be an LCD screen or an e-ink screen. The input devices can be a touch layer covering the display screen, buttons, a trackball, or a touchpad on the computer device's casing, or an external keyboard, touchpad, or mouse.

[0050] This embodiment also provides a storage medium storing a computer program that, when executed by a processor, implements the control optimization method for implementing an array-type photoacoustic transdermal patch as proposed in the above embodiments. The storage medium can be implemented by any type of volatile or non-volatile storage device or a combination thereof, such as Static Random Access Memory (SRAM), Electrically Erasable Programmable Read-Only Memory (EEPROM), Erasable Programmable Read Only Memory (EPROM), Programmable Red-Only Memory (PROM), Read-Only Memory (ROM), magnetic storage, flash memory, magnetic disk, or optical disk.

[0051] In summary, this invention overcomes the limitations of traditional equipment that uses a fixed sound velocity assumption, which cannot adapt to the non-uniformity and individual differences of human tissue, by inverting the equivalent sound velocity of tissue based on the phase characteristics of the echo signal. It solves the problem of phase distortion caused by medium mismatch, provides real physical parameter support for deep focusing, and effectively counteracts the energy loss and defocusing effect of sound waves in non-uniform media by combining real coordinates and sound velocity to calculate nonlinear propagation delay and plan theoretical sound intensity distribution, thus achieving high energy density focusing and sidelobe suppression at the focal point.

[0052] It should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit it. Although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that modifications or equivalent substitutions can be made to the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention, and all such modifications or substitutions should be covered within the scope of the claims of the present invention.

Claims

1. A method for controlling and optimizing an array-type photoacoustic transdermal patch, characterized in that: include: The strain sensing network integrated into the flexible patch is used to collect the geometric deformation data of the patch in real time, and the actual physical coordinates of each element in the photoacoustic transducer array in three-dimensional space are calculated based on the geometric deformation data. The probe acoustic pulse is emitted to the target tissue and the echo signal is received. The equivalent sound velocity of the tissue medium is obtained by inversion based on the phase characteristics of the echo signal. The propagation path delay from each array element to the preset focus is calculated based on the actual physical coordinates and the equivalent sound velocity, and the theoretical sound intensity distribution required to achieve focusing is calculated based on the propagation path delay. Based on the theoretical sound intensity distribution and the material property parameters of the acoustic metamaterial, the initial excitation power density required to drive the acoustic metamaterial array is calculated. A composite driving signal containing timing control and amplitude modulation is generated based on the propagation path delay and the initial excitation power density. The composite driving signal is used to excite the acoustic metamaterial array to generate resonant acoustic flow to perform transdermal drug delivery, and photoacoustic feedback signals inside the tissue are collected simultaneously. The cumulative drug dose is monitored in real time based on the photoacoustic feedback signal, and the drive signal output is terminated when the preset threshold is reached.

2. The control and optimization method for array-type photoacoustic transdermal patches as described in claim 1, characterized in that: The process involves real-time acquisition of geometric deformation data of the flexible patch through a strain sensing network integrated into the patch, and calculation of the actual physical coordinates of each element in the photoacoustic transducer array in three-dimensional space based on the geometric deformation data. The specific steps are as follows: By utilizing a distributed fiber optic grating sensor array pre-integrated within the flexible patch substrate, the axial tensile strain and bending strain generated after the patch is applied to the surface of human skin are monitored in real time, and the wavelength drift data of each sensor node due to deformation is obtained. The wavelength drift data is input into the polynomial surface fitting algorithm model, and the three-dimensional surface geometric equation of the flexible patch in the current application state is reconstructed through spatial interpolation. Based on the aforementioned three-dimensional surface geometric equations, a coordinate transformation matrix is ​​used to perform nonlinear mapping operations on the preset relative position vectors of the array elements, thereby accurately calculating the actual physical coordinates of each array element in the photoacoustic transducer array in three-dimensional space. ; Among them, calculating the actual physical coordinates The expression is: ; in, Indicates the first The actual three-dimensional spatial coordinate vector of each array element in the applied state. Indicates the overall bending angle of the patch. and torsion angle The constructed rigid body rotation matrix, This represents the initial position vector of the array element when the flexible patch is in an undeformed planar state. This represents the surface strain distribution function acquired by a distributed fiber Bragg grating sensor array. This represents the scalar potential gradient operator that describes the deformation gradient of the flexible patch surface. This represents the integral surface area region of the flexible patch.

3. The control and optimization method for array-type photoacoustic transdermal patches as described in claim 2, characterized in that: The steps of transmitting a probe acoustic pulse to the target tissue and receiving the echo signal, and then inverting the equivalent sound velocity of the tissue medium based on the phase characteristics of the echo signal, are as follows: The central element in the photoacoustic transducer array is controlled to emit broadband ultrasonic detection pulses toward deep target tissue, while the receiving elements at the edge of the array capture the echo signal scattered by the tissue medium. The echo signal is subjected to Hilbert transform processing, envelope detection and instantaneous phase extraction to obtain high-precision instantaneous phase difference data; A sound velocity inversion model based on the time-of-flight method and phase correction is constructed. The instantaneous phase difference data is used to correct the propagation time of sound waves in tissue, thereby obtaining the equivalent sound velocity in the tissue medium. ; Among them, the equivalent sound velocity of the tissue medium is calculated. The expression is: ; in, This represents the equivalent average sound velocity of the tissue medium obtained through inversion. This indicates the physical distance between the center of the transmitting element and the center of the receiving element. This represents the time flight delay of the echo signal envelope peak relative to the start of the transmitted pulse. Indicates the center frequency of the detected acoustic pulse. This represents the complex analytic signal after the echo signal undergoes the Hilbert transform. The operator represents the operation of taking the imaginary part of a complex number. Operators that take the real part of a complex number.

4. The control and optimization method for array-type photoacoustic transdermal patches as described in claim 3, characterized in that: The specific steps for calculating the propagation path delay from each array element to the preset focus based on the actual physical coordinates and the equivalent sound velocity, and calculating the theoretical sound intensity distribution required for focusing based on the propagation path delay, are as follows: Using the Euclidean distance formula, the straight-line distance between the actual physical coordinates of each element in the photoacoustic transducer array in three-dimensional space and the coordinates of the preset treatment focus is calculated to obtain the geometric propagation distance of each element. Divide the geometric propagation distance by the equivalent sound speed of the tissue medium and normalize the result to obtain the initial propagation delay of each array element. An acoustic attenuation coefficient is introduced to nonlinearly compensate for the initial propagation delay, thereby offsetting the energy loss and phase distortion of sound waves propagating in non-uniform structures and determining the propagation path delay of each array element. ; Among them, the propagation path delay is calculated. The expression is: ; in, Indicates the first The propagation path delay of each array element to the preset focus. Indicates the first The actual physical coordinates of each array element in three-dimensional space The spatial coordinate vector representing the preset treatment focus. Operators representing Euclidean norms Represents the equivalent speed of sound in the tissue medium. The attenuation factor represents the non-uniformity of the tissue medium. This represents the characteristic attenuation length constant of sound waves in tissue.

5. The control and optimization method for array-type photoacoustic transdermal patches as described in claim 4, characterized in that: The specific steps for calculating the initial excitation power density required to drive the acoustic metamaterial array based on the theoretical sound intensity distribution and the material property parameters of the acoustic metamaterial are as follows: Based on the piezoelectric constitutive equation, the electromechanical coupling coefficient and dielectric loss of the acoustic metamaterial array are mathematically modeled, and the energy conversion efficiency factor is calculated. Based on the theoretical sound intensity distribution, the energy density requirement value required to achieve an effective therapeutic effect at the target focal point is defined. By using a nonlinear acoustic flow effect model, the energy conversion efficiency factor and the energy density requirement are coupled and calculated to determine the initial excitation power density required to drive the acoustic metamaterial array. ; Among them, the initial excitation power density is calculated. The expression is: ; in, This represents the initial excitation power density required to drive the acoustic metamaterial array. This represents the target intensity value of the theoretical sound intensity distribution required to achieve focusing. This indicates the electromechanical coupling energy conversion efficiency of acoustic metamaterials. The acoustic nonlinear parameters representing the tissue medium, Indicates the density of the target tissue. It represents the equivalent speed of sound in the tissue medium.

6. The control and optimization method for array-type photoacoustic transdermal patches as described in claim 5, characterized in that: The specific steps for generating a composite driving signal containing timing control and amplitude modulation based on the propagation path delay and the initial excitation power density are as follows: High-frequency carrier pulse sequences are generated using field-programmable gate arrays (FPGAs). Based on the propagation path delay, digital phase shift control is performed on each channel of the high-frequency carrier pulse sequence to generate precise timing control components. Based on the initial excitation power density, the pulse duty cycle of the timing control component is pulse-width modulated to generate the corresponding amplitude modulation component; The timing control component and the amplitude modulation component are logically superimposed and synthesized to generate a composite drive signal for driving the transducer.

7. The control and optimization method for array-type photoacoustic transdermal patches as described in claim 6, characterized in that... The specific steps of using the composite driving signal to excite the acoustic metamaterial array to generate resonant acoustic flow for transdermal drug delivery, and simultaneously acquiring photoacoustic feedback signals from within the tissue, are as follows: The composite driving signal is applied to the piezoelectric excitation end of the acoustic metamaterial array to excite the acoustic flow effect at the micro-nano scale, and instantaneously open the skin stratum corneum channel to perform transdermal drug delivery. By utilizing a photodiode array integrated on the back of the patch, the photoacoustic response light waves generated by the stimulation of drug molecules inside the tissue can be received in real time. Lock-in amplification technology is applied to perform high signal-to-noise ratio noise reduction on the photoacoustic response light wave, and the photoacoustic feedback signal is accurately extracted from it.

8. The control and optimization method for array-type photoacoustic transdermal patches as described in claim 7, characterized in that: The step of monitoring the cumulative drug dosage in real time based on the photoacoustic feedback signal and terminating the drive signal output when a preset threshold is reached is as follows: Based on the acoustic equivalent form of Lambert-Beer's law, the amplitude of the photoacoustic feedback signal is analyzed to calculate the real-time transient drug concentration. Using the trapezoidal integral rule, the transient drug concentration is continuously accumulated over the dosing time axis to obtain the cumulative drug dose. ; Among them, the cumulative drug dose is calculated. The expression is: ; in, This indicates the real-time cumulative drug dose. Indicates the moment when transdermal drug delivery begins. Indicates the current system time. This represents the photoacoustic conversion efficiency constant of drug molecules. express The amplitude of the photoacoustic feedback signal collected at all times, This represents the system background noise floor amplitude. This represents the natural logarithm operator.

9. A computer device comprising a memory and a processor, wherein the memory stores a computer program, characterized in that: When the processor executes the computer program, it implements the steps of the control optimization method for the array-type photoacoustic transdermal patch according to any one of claims 1 to 8.

10. A computer-readable storage medium having a computer program stored thereon, characterized in that: When the computer program is executed by the processor, it implements the steps of the control optimization method for the array-type photoacoustic transdermal patch according to any one of claims 1 to 8.